JonathanSSerodyMD

Hematologic Oncology

Elizabeth Thomas Professor of Medicine Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine; Division Chief of Hematology

Join to view full profile

Dr. Serody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Serody's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-4996

Fax+1 919-843-5515

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1993 - 1993
University of North Carolina HospitalsFellowship, Infectious Disease, 1989 - 1993
University of North Carolina HospitalsResidency, Internal Medicine, 1986 - 1989
University of Virginia School of MedicineClass of 1986

Certifications & Licensure

NC State Medical License 1988 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Elizabeth Thomas Professor of Medicine University of North Carolina, 2006

Clinical Trials

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 2

Publications & Presentations

PubMed

Corrigendum to "Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy" [Biom...
Mostafa Yazdimamaghani, Oleg V Kolupaev, Chaemin Lim, Duhyeong Hwang, Sonia J Laurie
Biomaterials. 2025-03-01
2 citations
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.
Mostafa Yazdimamaghani, Oleg V Kolupaev, Chaemin Lim, Duhyeong Hwang, Sonia J Laurie
Biomaterials. 2025-01-01
Optimized Fabrication of Dendritic Mesoporous Silica Nanoparticles as Efficient Delivery System for Cancer Immunotherapy.
Varsha Godakhindi, Mostafa Yazdimamaghani, Sudip Kumar Dam, Farzana Ferdous, Andrew Z Wang
Small. 2024-12-01

Journal Articles

Endogenous Retrovirus Expression Is Associated with Response to Immune Checkpoint Blockade in Clear Cell Renal Cell Carcinoma
Benjamin G. Vincent, Jonathan S. Serody, Gregory Riedlinger, Shridar Ganesan, The Journal of Clinical Investigation
Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
Jonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Jonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD
Jonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Jonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Putting the 'STING' on CAR-T Cells to Turn Them Against Breast Cancer and Other Solid TumorsJanuary 4th, 2021
Excellent Research Results for CAR-T Cell Therapy Against Hodgkin LymphomaJuly 23rd, 2020
ASCO Announces 2020 AwardsApril 24th, 2020
Join now to see all

Grant Support

Evaluating the Immune Infiltrate in Basal-like and Claudin-low Breast CancerNational Cancer Institute2012–Present
Targeting Lymphoid Migration for the Prevention/Treatment of GVHDNational Heart Lung and Blood Institute2012–Present
Evaluating the Interaction of T cells and Macrophages in Cutaneous GVHDNational Cancer Institute2012–Present
Treg Migration In GVHDNational Institute Of Allergy And Infectious Diseases2011
Modeling TH17 Cells In Acute GVHDNational Institute Of Allergy And Infectious Diseases2010
Breast Cancer Vaccine Strategies For Her2-Overexpressing And Lum. B TumorsNational Cancer Institute2006–2010
Treg Migration In GVHDNational Institute Of Allergy And Infectious Diseases2005–2009
Clinical Trial: Lccc 0418: Phase I/II Multieptitope Dendritic Cell Vaccine In BNational Center For Research Resources2008
Lccc 0418: Phase I/II Multieptitope Dendritic Cell Vaccine In Breast CancerNational Center For Research Resources2007
Lccc 0310 Dendritic Cell Vaccine Given With Trastuzumab And VinorelbineNational Center For Research Resources2005–2007
Mechanisms Involved In T Cell Trafficking In GVHDNational Cancer Institute2003–2007
Multimodality Therapy For Metastatic Breast CancerNational Cancer Institute2005–2006
Enhancing A Breast Cancer VaccineNational Cancer Institute2001–2002
Immunotherapy For Metastatic Breast CancerNational Cancer Institute2000–2001
ID Of Epitopes From CML Recognized By T CellsNational Cancer Institute1996–2000
Cloning And Regulation Of A Lactoferrin Receptor GeneNational Institute Of Allergy And Infectious Diseases1991